Crinetics Pharmaceuticals CRNX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Crinetics Pharmaceuticals (CRNX) Core Market Data and Business Metrics
Latest Closing Price
$31.39Price-Earnings Ratio
-8.46Total Outstanding Shares
93.05 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
10222 Barnes Canyon Road, Bldg. #2, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 946,856 Shares | 8.21 | 3/14/2025 | 7,771,573 Shares |
| 1,128,565 Shares | 7.18 | 2/28/2025 | 8,108,504 Shares |
| 671,989 Shares | 11.6 | 2/14/2025 | 7,796,164 Shares |
| 1,048,679 Shares | 7.04 | 1/31/2025 | 7,380,396 Shares |
| 1,268,982 Shares | 5.65 | 1/15/2025 | 7,169,914 Shares |
| 786,679 Shares | 8.8 | 12/31/2024 | 6,919,827 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $174.47 Million |
| Net Cash Flow From Investing Activities | $-120.04 Million |
| Net Cash Flow From Operating Activities, Continuing | $-199.81 Million |
| Net Cash Flow From Investing Activities, Continuing | $-120.04 Million |
| Net Cash Flow, Continuing | $174.47 Million |
| Net Cash Flow From Operating Activities | $-199.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $307.81 Million |
| Costs And Expenses | $299.73 Million |
| Diluted Average Shares | $234.46 Million |
| Depreciation and Amortization | $2.26 Million |
| Net Income/Loss | $-277.91 Million |
| Benefits Costs and Expenses | $218.54 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-275.01 Million |
| Other Comprehensive Income/Loss | $-6.91 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-275.01 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $877.59 Million |
| Equity | $832.98 Million |
| Noncurrent Liabilities | $50.83 Million |
| Assets | $937.37 Million |
| Current Liabilities | $53.56 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||